Clinical trials: Motor Neurone Disease
Amyotrophic Lateral Sclerosis
HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
- Trial name
- NCT05136885
- Testing
- SLS-005
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Merit E. Cudkowicz, MD
Stroke, Muscle Spasticity
Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function
The purpose of this study is to evaluate the safety of injections of botulinum toxin Type A in patients with reduced lung function and focal upper limb poststroke spasticity
- Conditions
- Stroke, Muscle Spasticity, Motor Neuron Disease
- Trial name
- NCT00076687
- Testing
- botulinum toxin Type A, saline
- Where
- 4 sites in United States, Czechia and 2 more
- Volunteers
- 155 people
- Sponsor
- Allergan
Spinal Muscular Atrophy 1
Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1
The purpose of this trial is to evaluate safety and efficacy of intravenous delivery of AVXS-101 as a treatment of spinal muscular atrophy Type 1 (SMN1).
- Trial name
- NCT02122952
- Testing
- AVXS-101
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Novartis Gene Therapies
Amyotrophic Lateral Sclerosis
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)
This is a Phase II screening study of lithium carbonate in ALS. The purpose of this study is to find out if lithium carbonate is safe to be used in people with ALS and if it can slow the progression of the disease.
- Trial name
- Lithium (NCT00790582)
- Testing
- lithium carbonate
- Where
- 10 sites in United States
- Volunteers
- 109 people
- Sponsor
- Forbes Norris MDA/ALS Research Center
Spinal Muscular Atrophy
A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
The primary objective of the study is to examine the efficacy of multiple doses of Nusinersen administered intrathecally in preventing or delaying the need for respiratory intervention or death in infants with genetically…
- Trial name
- NURTURE (NCT02386553)
- Testing
- Nusinersen
- Where
- 21 sites in United States, Australia and 5 more
- Volunteers
- 25 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis
Electrical Impedance Myography as an Outcome Measure in Amyotrophic Lateral Sclerosis Clinical Trials
Trials evaluating new therapies for stopping or slowing the progression of ALS depend critically upon the use of outcome measures to assess whether a potential treatment is effective.
- Trial name
- NCT00620698
- Where
- 8 sites in United States
- Volunteers
- 89 people
- Sponsor
- Beth Israel Deaconess Medical Center
Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3
An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
The TOPAZ study will assess the safety and efficacy of SRK-015 in later-onset Spinal Muscular Atrophy (SMA Type 2 and Type 3) in pediatric and adult patients.
- Conditions
- Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA
- Trial name
- TOPAZ (NCT03921528)
- Testing
- SRK-015
- Where
- 16 sites in United States, Italy and 2 more
- Volunteers
- 58 people
- Sponsor
- Scholar Rock, Inc.
ALS (Amyotrophic Lateral Sclerosis)
A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients
The goal of this VA demonstration project is to show that the Brain-computer interface (BCI) technology is a clinically practical and important new communication and control option that can improve the lives of veterans with…
- Trial name
- ALS (NCT00786032)
- Testing
- BCI Device
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- US Department of Veterans Affairs
Amyotrophic Lateral Sclerosis
Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS
This study will evaluate whether prolonged oral levosimendan can preserve respiratory function more effectively than placebo, resulting in better patient functionality as measured by the ALSFRS-R scale.
- Trial name
- REFALS (NCT03505021)
- Testing
- Levosimendan
- Where
- 104 sites in United States, Australia and 12 more
- Volunteers
- 496 people
- Sponsor
- Orion Corporation, Orion Pharma
Primary Lateral Sclerosis
Transcutaneous Electrical Stimulation for Spasticity in Patients With Primary Lateral Sclerosis
The goal of this clinical trial is to determine if non-invasive electrical stimulation, using an electric stimulator placed on the skin of the patients back and abdomen for 30 minutes can reduce muscle spasms (spasticity) and…
- Trial name
- NCT06012110
- Testing
- Transcutaneous electrical stimulation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Nova Southeastern University
Amyotrophic Lateral Sclerosis
Clinical Trial of Ezogabine (Retigabine) in ALS Subjects
This study evaluates the effect of retigabine (600 mg/day, 900 mg/day, or placebo) on motor neuron activity in people with Amyotrophic Lateral Sclerosis (ALS). The total study duration is approximately 14 weeks.
- Trial name
- NCT02450552
- Testing
- Ezogabine
- Where
- 12 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Brian Wainger
Amyotrophic Lateral Sclerosis, Respiratory Muscle Weakness
ALS and Airway Clearance (ALSAC) Therapy
Patients will receive one of three respiratory therapy interventions for airway clearance assistance: 1) High frequency chest wall oscillation (HFCWO) and mechanical insufflation/exsufflation (MIE), 2) HFCWO or 3) MIE.
- Trial name
- ALSAC (NCT04947436)
- Testing
- High Frequency Chest Wall Oscillation, Mechanical insufflation/exsufflation
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Cystic Fibrosis, Motor Neuron Disease
MN4000 for Treatment of CF and MND Patients in the Home Setting
The study was a non-randomized open label pilot study. It was an observational design conducted at one (1) site in the US. All enrolled subjects received treatment with the MN4000.
- Conditions
- Cystic Fibrosis, Motor Neuron Disease, Airway Clearance Impairment
- Trial name
- NCT03797677
- Testing
- MN 4000
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hill-Rom
Amyotrophic Lateral Sclerosis (ALS)
Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
ALS is a disorder that weakens motor strength and lung function. Rapid loss of motor neurons in the brain and spinal cord of ALS patients causes the symptoms of increasing weakness and loss of muscle function.
- Trial name
- NCT01786603
- Testing
- Rasagiline
- Where
- 10 sites in United States
- Volunteers
- 80 people
- Sponsor
- Richard Barohn, MD
Amyotrophic Lateral Sclerosis
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
This study assessed the effect of tirasemtiv versus placebo on respiratory function in patients with ALS.
- Trial name
- VITALITY-ALS (NCT02496767)
- Testing
- Tirasemtiv
- Where
- 81 sites in United States, Belgium and 9 more
- Volunteers
- 744 people
- Sponsor
- Cytokinetics
Amyotrophic Lateral Sclerosis
Phase 3 Extension Study of Dexpramipexole in ALS
The purpose of the study is to collect long-term safety data from subjects with Amyotrophic Lateral Sclerosis (ALS) exposed to dexpramipexole.
- Trial name
- ENVISION (NCT01622088)
- Testing
- Dexpramipexole
- Where
- 80 sites in United States, Australia and 9 more
- Volunteers
- 616 people
- Sponsor
- Knopp Biosciences
Amyotrophic Lateral Sclerosis, ALS
Clinical Trial Ceftriaxone in Subjects With ALS
The purpose of the study is to evaluate the safety and efficacy of ceftriaxone treatment in amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT00349622
- Testing
- ceftriaxone
- Where
- 58 sites in United States, Canada
- Volunteers
- 513 people
- Sponsor
- Massachusetts General Hospital
Spinal Muscular Atrophy
An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy
This study will test the safety, tolerability, and pharmacokinetics of escalating doses of nusinersen (ISIS 396443) administered into the spinal fluid either two or three times over the duration of the trial, in participants with…
- Trial name
- NCT01703988
- Testing
- Nusinersen
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis, Frontal Temporal Dementia
Therapy in Amyotrophic Lateral Sclerosis (TAME)
The purpose of this study is to determine if memantine at up to 20 mg twice a day when used in conjunction with riluzole, can slow down the disease progression of patients with ALS including potentially improving their…
- Trial name
- TAME (NCT02118727)
- Testing
- Memantine
- Where
- 13 sites in United States
- Volunteers
- 89 people
- Sponsor
- University of Kansas Medical Center
Amyotrophic Lateral Sclerosis
Geometrical Facial Deformation According to Posture in Amyotrophic Lateral Sclerosis
The measurement of the facial deformation according to the body posture will be conducted by 3D scanning for each posture after marking the landmarks on the face.
- Trial name
- NCT04798183
- Testing
- 3-dimensional scan
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pusan National University Yangsan Hospital